Delamanid + OBR
242-09-213
Phase 3 small_molecule completed
Quick answer
Delamanid + OBR for Multidrug-resistant Tuberculosis is a Phase 3 program (small_molecule) at Otsuka Beijing Research Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Otsuka Beijing Research Institute
- Indication
- Multidrug-resistant Tuberculosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed